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Abstract
Although simple and low-cost interventions for sickle cell disease (SCD) exist in
many developing countries, child mortality associated with SCD remains high, in
part, because of the lack of access to diagnostic tests for SCD. A density-based
test using aqueous multiphase systems (SCD-AMPS) is a candidate for a low-cost,
point-of-care diagnostic for SCD. In this paper, the field evaluation of SCD-AMPS in
a large (n5505) case-control study in Zambia is described. Of the two variations of
the SCD-AMPS used, the best system (SCD-AMPS-2) demonstrated a sensitivity
of 86% (82–90%) and a specificity of 60% (53–67%). Subsequent analysis
identified potential sources of false positives that include clotting, variation between
batches of SCD-AMPS, and shipping conditions. Importantly, SCD-AMPS-2 was
84% (62–94%) sensitive in detecting SCD in children between 6 months and 1 year
old. In addition to an evaluation of performance, an assessment of end-user
operability was done with health workers in rural clinics in Zambia. These health
workers rated the SCD-AMPS tests to be as simple to use as lateral flow tests for
malaria and HIV.
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Timely diagnosis of sickle cell disease (SCD) is essential for effective intervention.
The difficulty of diagnosis of SCD in low-resource settings, however, means that
over half of the more than 300,000 children born each year with this disorder die
before five years of age [1,2]. Measuring the mass density (g/cm
3) of populations
of erythrocytes provides a potential route to a low-cost, fieldable diagnostic for
SCD. Density is a relevant biophysical characteristic differentiating red blood cells
of a person with SCD from those cells of a person without the disease. The
dehydration associated with sickling causes an increase in the density of an
erythrocyte, from approximately 1.095 g/cm
3 to over 1.120 g/cm
3 [3,4]. The
dense, and often sickled, cells present in SCD are denser than the densest cells in
the natural distribution of the density of normal erythrocytes.
We previously described the use of aqueous multiphase systems (AMPSs)—
mixtures of polymers in water that form immiscible, liquid phases—to separate
erythrocytes by density, and thus, to provide a rapid visual test for SCD [5]. Four
characteristics make AMPSs suitable for density-based separations at the point-of-
care: i) Thermodynamic Stability. Step-gradients can be made centrally and will
reform after disturbances from transportation. ii) Fine Resolution in Density. The
interface between the liquid phases of AMPSs provide a molecularly sharp step in
density between phases with differences in density as low as 0.001 g/cm
3 [6]. iii)
Scalability in Manufacturing. Reproducible step gradients can be made by making
large batches (.1 L) of an AMPS and then aliquoting smaller volumes (,14 mL)
of the AMPS into capillary tubes appropriate for separating microliters of blood
obtained from a finger prick, and iv) Low Cost. Using commercially available
polymers, the cost of reagents, packaging, and labor per test is ,$0.50 [5].
Although previous testing of AMPS as a density-based diagnostic for sickle cell
disease (SCD-AMPS) in a U.S. laboratory setting showed both sensitivity and
specificity near or over 90% [5], implementing the test in point-of-care settings
introduces several additional variables, such as accuracy in quality control,
methods of packaging, conditions of storage and shipping, shelf-life, and
variability in the skills and experience of end-users. These variables could reduce
the sensitivity and specificity of a rapid test either via the tests themselves (e.g.,
dehydration could affect the assay) or the differences in operators (e.g., less
experienced readers may have a lower diagnostic accuracy). Previous work on a
paper-based test for liver function demonstrated that diagnostic accuracy could
decrease from over 90% [7] to 84% [8] when tests were taken from a laboratory
setting to a field setting. Evaluating tests in a field setting could illuminate issues
in production, use, or interpretation that could be addressed with an improved
design.
Testing SCD-AMPS on a larger population would also capture a greater
diversity of samples. With a larger sample size, we could capture a larger range of
conditions (e.g., severe anemia, a and b thalassemias) that could affect the
performance of a density-based test. To understand how these issues might affect
the SCD-AMPSs tests, we undertook a 505-subject case-control study at the
patent filed regarding the use of aqueous multi-
phase systems to diagnose sickle cell disease
(U.S. Patent Application No. 61/816,227). This
does not alter the authors’ adherence to PLOS
ONE policies on sharing data and materials.
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prevalent.
We tested two prototypes, both of which demonstrated the ability to identify
SCD with a diagnostic accuracy (defined as the total correct calls—true positives
and true negatives—over the total number of samples tested) 69%. Based on the
results of this study, we identified three key issues that could be addressed in
continuing work to improve the performance of future prototypes: 1) variability
in the density of the bottom phase between batches, 2) conditions of shipping and
storage, and 3) clotting of blood samples. We also performed surveys of health
workers in two rural health centers in a part of Zambia estimated to have a high
prevalence of SCD [9]. The surveys captured current knowledge of the disease,
experience with other rapid tests, and feedback on the design of the proposed
rapid test for SCD.
Experimental Design
Rapid Test Design
We evaluated two different density-based tests: a system with two phases, SCD-
AMPS-2, and a system with three phases, SCD-AMPS-3 (Fig. 1). Sickling is
concomitant with the dehydration of red blood cells. The resulting deformed cells
have a marked increase in density. By tuning the density of the bottom phase of an
AMPS to retain cells with normal densities and only allow very dense cells
(Dr.1.120 g/cm
3) to pass to the bottom of the AMPS, we can provide a visual
test for dense cells that may correlate with the presence of SCD [5]; red blood cells
at the bottom interface (i.e., between the bottom phase and the seal of the
container) create a red layer. The design of the bottom phase is common to both
SCD-AMPS-2 and SCD-AMPS-3. The top phase in both systems separates plasma
from cells and ensures that cells stack at well-defined interfaces rather than a
diffusive liquid/liquid boundary. The third phase in SCD-AMPS-3 provides an
additional phase and interface to separate cells in the lower density range of
erythrocytes.
Although SCD-AMPS-2 allows for a simpler interpretation, SCD-AMPS-3
provides a richer set of information about the distribution of densities of
erythrocytes; this information can help distinguish between the two main
genotypes of SCD: Hb SS and Hb SC [5]. We evaluated both tests in the study to
see if the simplicity of the two-phase test conferred a distinguishable advantage
over the additional information available in the three-phase tests, in an actual
clinical setting.
We used the design of the rapid test described previously [5] with some
additional modifications to enable rapid assembly of the tests, and to improve
durability for shipping and storage (S1 Figure). A mixture of 7.0% (w/v)
poly(ethylene glycol) (PEG) with a molecular weight (MW) of ,20 kD, 10.3%
(w/v) Ficoll with a MW of ,400 kD, and 9.1% (w/v) Nycodenz formed SCD-
AMPS-2 (rtop51.078 g/cm
3 and rbot51.129 g/cm
3). Similarly, a mixture of 3%
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PLOS ONE | DOI:10.1371/journal.pone.0114540 December 9, 2014 3/2 4Fig. 1. Schematic of the density-based tests to identify SCD. Both versions of the SCD-AMPS are
designed to separate dense red blood cells present in SCD from whole blood. Blood passes through the
phases—top (T) and bottom (B) for SCD-AMPS-2 and top (T), middle (M), and bottom (B) for SCD-AMPS-3—
upon centrifugation. If sickled cells are present, they collect at the interface between the bottom phase and the
seal (B/S), and provide a visual readout for the presence of SCD. In SCD-AMPS-3, the additional phase
allows the discrimination of Hb SS from Hb SC by evaluating the distribution of red cells at the upper
interfaces (between the top and middle phases (T/M) and the middle and bottom phases (M/B).
doi:10.1371/journal.pone.0114540.g001
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5% (w/v) polymer of partially hydrolyzed poly(vinyl acetate) (containing 75% -
OH and 25% -OCOCH3 groups) with a MW of ,3 kD, and 8.7% (w/v)
Nycodenz, formed SCD-AMPS-3 (rtop51.077 g/cm
3, rmid51.108 g/cm
3, and
rbot51.120 g/cm
3). We buffered the systems, and used NaOH and HCl to adjust
the pH of the solutions to 7.40¡0.02 and NaCl to adjust the osmolality to
295¡15 mOsm/kg (S1 Text).
S2 Figure outlines the process to perform a rapid test for an end-user. The self-
forming step-gradient in density allows the end-user to use the AMPS out of a
packet without needing to mix reagents or pipette solutions. A drop of whole
blood wicks directly into the capillary; no further handling of blood is necessary.
Preparative steps common to other techniques, such as lysis or exposure to
reagents to deoxygenate hemoglobin [10,11], are not needed. These character-
istics of the test reduce risks for biohazards and error by users. The polycarbonate
capillary tubes that house the rapid test are preloaded with AMPS and sealed on
one end with white, vinyl-based putty (Critoseal, Leica). The white seal provides
an effective background to contrast with the red cells. A volume of 5.0¡0.2 mLo f
blood enters the rapid test via capillary action; the volume is limited by the pre-
punched hole in the side of the capillary. We used a 3D printed mold and a
pushpin to make repeatable holes; this standardization allowed us to load a
reproducible volume of blood with a coefficient of variance (CV) of 4% (S1 Text).
Sliding a silicone sleeve over the hole prevents the blood from leaking, and
centrifugation accelerates the density-based separation of red blood cells across
the steps in density of the AMPS. After 10 minutes of centrifugation at 13,700 g,
evaluating the interfaces of AMPS for the visible presence of red cells provides a
means to identify SCD and, in the case of SCD-AMPS-3, to distinguish between
the two main genotypes of SCD (Fig. 1)[ 5].
Development of Methods to Pack, Store, and Ship SCD-AMPS
Tests
We performed a series of accelerated storage tests using various packaging
materials and methods (S1 Text). Individual capillaries were sealed on each end,
and the hole in the side of the tube was covered with the silicone sleeve before
packaging. We found that foil-lined pouches to which we had added 4 mL of
water, and then sealed with an impulse sealer, minimized evaporation of the water
from the AMPS in the tubes. To minimize variables for this clinical trial, we
refrigerated the rapid tests after packaging at 4–8˚C and shipped them on ice to
Zambia. On arrival in Zambia, the staff at UTH stored the samples at 4˚C. We
brought the tests to room temperature on the day of use. Each batch of packaged
tests was used within two months of the packaging date. Future work will define
the shelf life and stability of the tests during storage at ambient temperatures.
Field Evaluation of a Density-Based Rapid Test for Sickle Cell Disease
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The initial study in Zambia included 505 children that were seen as out-patients
or in-patients between June and December, 2013, in the Department of
Paediatrics and Child Health and the hematology unit for SCD patients at UTH.
We used the broad inclusion and exclusion criteria found in Table 1, with further
criteria for specific subsets of the study population: Subset 1) children fitting the
inclusion criteria with the additional inclusion criteria of being over one year old
and confirmed as SCD positive, Subset 2) children fitting the inclusion criteria
above with the additional inclusion criterion of not having SCD, Subset 3)
children fitting the inclusion criteria with the additional inclusion criteria of being
below one year old and confirmed as SCD positive, and Subset 4) children fitting
inclusion criteria with the exception of the first exclusion criteria who were over
one year old, confirmed as SCD positive, and had undergone a sickling crisis
within the last 48 hours.
The first two subsets were recruited to achieve a population with roughly 50%
SCD positive participants. These participants provide the main population of
interest in the study. The last two subsets were of interest to test potential
confounding factors for a field diagnostic. Specifically, before achieving one year
of age, infants may still have a large proportion of fetal hemoglobin, Hb F, in their
blood. This hemoglobin interferes with sickling and could reduce the percent of
the cells present that are dense, and reduce the sensitivity of a density-based assay
for this subset. An evaluation of this subset allowed us to determine whether there
was a difference between the predictive value of the SCD-AMPS test for children
below one year of age and children above one year of age. Similarly, participants
who have SCD and have recently experienced a sickle crisis may have cleared all
dense cells in their blood [12], although that finding has not been confirmed.
Table 2 details the the final populations used in the study.
The 505 subjects included in the study were a subset of 767 total subjects that
were recruited who fit the inclusion criteria. Of these 767 subjects, 43 were
excluded because their blood sample clotted or was of insufficient volume to
perform all the tests. A batch of SCD-AMPS tests sent to Zambia was made with
an incorrect buffer concentration. When this error was realized, the study staff
were informed to not use these tests but 60 subjects had already been tested with
them and were excluded from the main study. Of the 664 subjects remaining, 159
were not tested on SCD-AMPS until after 48 hours (outside the inclusion limit).
Eight of these were not tested until after 72 hours. The final number of subjects
that had usable samples run on valid tests within the proper timeframe was 505
(S3 Figure).
Collection of Samples
In both in-patient and out-patient clinics, we recruited participants who were
having blood drawn for clinically indicated reasons. An additional vial of blood
was collected for the study after consenting the participants. This blood was
aliquotted into two different samples. One sample was sent to a clinical laboratory
Field Evaluation of a Density-Based Rapid Test for Sickle Cell Disease
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separate laboratory at UTH to perform evaluation of the sample using standard
methods.
Evaluation of Samples by Standard Methods
We chose to evaluate the SCD-AMPS tests at UTH, a tertiary hospital, rather than
lower level clinics because of the need to compare results to standard methods.
UTH has well-established clinical laboratories capable of performing hemoglobin
electrophoresis (HE) and complete blood counts (CBCs), and they receive regular
shipments of reagents from vendors. Both HE and CBCs were performed on all
the samples. The rapid tests and confirmatory tests occurred at different
laboratories and were performed by separate personnel to ensure proper blinding
of the results. During the pilot phase of the study, we established the maximum
time between sample collection and testing for each type of analysis, as well as
other criteria that we used to bin samples as unusable (e.g. visible clots forming
and insufficient volume of blood to run all tests) (S1 Table). These criteria were
used to exclude samples or tests. Results from HE and CBC allowed us to classify
subjects as SCD, sickle cell trait, or non-SCD based on detecting the presence and
quantity of Hb S as well as evaluation of the red blood cell indices (S1 Text).
Table 1. Inclusion and Exclusion Criteria for Study.
Inclusion Criteria Exclusion Criteria
Children aged 6 months up to, but not including 18 years Children who have had a sickling crisis one month prior to the blood draw (except for
the subset specified below)
Children with clinical indication for a blood draw Children who have been treated with hydroxyurea in the last four months
Children whose parents give a written informed consent to be part
of the study
Children who have received a transfusion in the last four months
Children whose parent consent to have blood draw for clinical
purposes and for the study
doi:10.1371/journal.pone.0114540.t001
Table 2. Basic Characteristics of the Study Population.
Population Total
Subjects Male Female
Positive (Hb SS) 322 166 156
$1 yr, non-crisis 270 144 126
,1 yr, non-crisis 19 4 15
.1 yr, crisis 33 18 15
Negative 183 91 92
Hb AA 136 65 71
Hb AS 47 26 21
TOTAL 505 257 248
doi:10.1371/journal.pone.0114540.t002
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After a one-day period of training, readers (nurses and laboratory technicians at
the hospital) were instructed to evaluate each test by classifying the amount of red
color that was visible at each interface into bins: 1) no red cells detectable, 2) less
than half a layer of red cells, 3) over half a layer of red cells, 4) full layer of red
cells, or 5) majority of red cells (Fig. 2).
We chose to use these five classifications rather than a simple binary reading in
order to understand how different cut-offs could affect test performance. For the
previous study at Harvard University, we had used a full layer of red or more (i.e.
classification 4 or higher) at the bottom interface as the criterion for labeling
results as positive or negative, and, in the case of SCD-AMPS-3, the identification
of the majority of cells at the lower liquid interface (i.e. classification of 5) as
indication of the presence of either Hb SC or Hb CC [5]. Although the five
classifications added complexity to interpretation, they allowed a greater
resolution of the potential differences in the densities of cells.
Field visits to obtain feedback from end-users
We performed demonstrations of the rapid test, and took suggestions on the use
of the test, from the clinical staff at two rural health centers (RHCs) in the
Luwingu District of Northern Province, Luena RHC and Ipusukilo RHC. The
Northern Province is estimated to have a high prevalence of SCD [9]. We selected
the two centers in the Northern Province for their remote location with no access
to grid electricity or paved roads. At each site, over the course of two days, study
staff members provided an information session about sickle cell disease and
management for the clinical staff, community health workers, and the broader
community, as well as an information session and demonstration of the SCD-
AMPS-2 rapid test. Following these sessions, a survey of the clinical staff members
(who included nurses and clinical officers) and community health workers
assessed their familiarity with other rapid tests, and their thoughts on the SCD-
AMPS-2 rapid test. A member of the study team from Harvard performed the
demonstration of the test using his own blood in accordance with an IRB-
approved protocol.
Results and Discussion
The Packaging Method Prevented the Evaporation of Samples
All rapid tests were evaluated visually for irregularities after a short centrifugation
(2 minutes at 13,700 g) before use (S2 Figure), and the result of this inspection
was logged for the vast majority of the tests used (n5624). We found two modes
of failure of the rapid test after packaging, shipping, and storing. In 3.8% of the
tests, the plug from the rubber cap snapped upon removal from the tube, leaving
the capillary plugged and unusable. In 1.5% of the tests, we observed incorrect
liquid levels; 1.0% were under-filled and 0.5% were over-filled. Water could enter
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glue at the bottom of the test, 2) improper capping of the top of the test with the
rubber stopper, or 3) incomplete coverage of the hole in the side of the capillary
by the silicone sleeve. Notably, all tests formed the correct number of phases as
verified by visual inspection. The total failure rate for the packaging, shipping, and
storage of the rapid tests was 5.3%. Visual inspection without the short
centrifugation may be sufficient since phases always formed properly in such a
Fig. 2. Schematic representation of the five levels of evaluation of the bottom of an SCD-AMPS test.
Levels 1 through 5 correspond to increasing levels of accumulation of red cells at the interface between the
bottom phase and the seal (B/S) compared to the accumulation of red cells at the interface between the top
and bottom phase (T/B).
doi:10.1371/journal.pone.0114540.g002
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that failed these visual inspections were discarded and not used for testing blood
samples.
Performance of SCD-AMPS
We calculated the sensitivity and specificity of SCD-AMPS-2 and SCD-AMPS-3
using each of the five classifications for the level of red cells at the bottom interface
(i.e., the interface between the lower phase and the seal) (Table 3). We
constructed receiver operating characteristic curves using these calculations
(Fig. 3). The area under the curve (AUC) for SCD-AMPS-2 was 0.73 and for
SCD-AMPS-3 was 0.70. This indicates an ability to discriminate sickle cell disease,
but is lower than previous estimates of performance (AUC.0.95) found during
initial validation of these systems in a laboratory setting [5].
We used the threshold at which the product of the sensitivity and specificity
was highest as the evaluation threshold for each of the two SCD-AMPS. For SCD-
AMPS-3, this level was ‘‘less than half a red layer’’ at the bottom of the tube or
higher to be considered positive (Level 2). For SCD-AMPS-2, the cutoff was a
‘‘full layer of red’’ at the bottom of the tube or higher (Level 4). Using these
thresholds, visual readings of SCD-AMPS-2 provided a sensitivity of 87% with a
95% confidence interval (CI) of 82–90%, a specificity of 60% (CI 53–67%), and
an overall diagnostic accuracy of 77% (CI 73–81%); and SCD-AMPS-3 had a
sensitivity of 75% (CI 70–79%), a specificity of 60% (CI 53–67%), and an overall
diagnostic accuracy of 69% (CI 65–73%).
In 2013, the National Institute of Health (NIH) in the U.S. put out a request for
proposals to develop new point-of-care diagnostics for SCD. They suggested that
new tests should have a sensitivity of over 60% and a diagnostic accuracy of over
90% (RFA-HL-14-010). In children over 6 months old in this study, SCD-AMPS
demonstrate sensitivity well above the recommendation, but specificity will need
to be improved to achieve the suggested diagnostic accuracy. Furthermore,
evaluation on children below 6 months of age is still needed to assess whether a
density-based test could be used on newborns.
Part of the reduced specificity could be attributed to the bias of the readers at
UTH to read samples with a higher level of redness compared to the expert reader
(S1 Text). The use of a cell phone camera or portable scanner to analyze the rapid
tests would eliminate the subjectivity associated with visual inspection.
The trial in Zambia introduced several other variables that may have played a
role in lowering the performance as compared to results obtained with clinical
samples tested previously at Harvard University [5], and are potential areas for
improvement for development of this point-of-care diagnostic. We analyzed
several of these variables and concluded that three of them were the most probable
causes of the reduced performance: 1) storage and shipping conditions, 2)
variability in the batches of AMPS (S4 Figure, S2 Table)—particularly, variations
in the density of the bottom phase between batches—and 3) clotting (S1 Text).
Field Evaluation of a Density-Based Rapid Test for Sickle Cell Disease
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SCD-AMPS-2 Hemoglobin Electrophoresis
SCD Negative SCD Positive
Red Level at Bottom AA AS SS AS*
(1) None 82 28 37 6
(2) Under half layer 5 1 21 2
(3) Over half layer 10 5 55 0
(4) Full layer 39 13 196 4
(5) Majority of red 0 0 1 0
Excluded 140 17 58 4
SCD-AMPS-3 Hemoglobin Electrophoresis
SCD Negative SCD Positive
Red Level at Bottom AA AS SS AS*
(1) None 39 17 18 4
(2) Under half layer 21 4 12 1
(3) Over half layer 19 10 44 3
(4) Full layer 57 16 236 4
(5) Majority of red 0 0 0 0
Excluded 140 17 58 4
*Samples found to have.50% Hb S but non-zero levels of Hb A, potentially a result of Hb S with b-thalassemia or a transfused Hb SS subject.
doi:10.1371/journal.pone.0114540.t003
Fig. 3. Receiver Operating Characteristic (ROC) curves of SCD-AMPS-2 and SCD-AMPS-3 including all
data from Zambia shows fair discriminative ability. The amount of red cells below the bottom phase of
each test was evaluated by eye and classified on a five point scale. Both tests showed an ability to
discriminate sickle cell disease from non-disease. In general, the specificity was lower than the sensitivity of
the tests.
doi:10.1371/journal.pone.0114540.g003
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during the course of the study (a sixth batch was also used, but was incorrectly
formulated and, thus excluded). Comparing the diagnostic accuracy of each batch
with Fisher’s exact test shows that performance of both SCD-AMPS varied
significantly (p-value ,0.001) between batches. Slight variations in the density of
the bottom phase of each batch may have influenced the performance of the tests;
this issue could be addressed by implementing tighter quality control at the site of
production and by developing density standard beads for the tests to provide
experimental controls. All batches were shipped with ice packs via FedEx,
generally arriving at UTH five days after dispatch from Harvard. The third batch,
however, was delayed in transit due to a fire at the Nairobi International Airport
that disrupted travel and shipping throughout sub-Saharan Africa. This batch
took ten days to arrive at UTH. The SCD-AMPS-2 from Batch 3 had the second
lowest diagnostic accuracy of the batches, and the SCD-AMPS-3 tests from that
batch had the lowest diagnostic accuracy of all batches (S4 Figure). Without data
loggers for temperature and humidity, we can only speculate about whether the
additional transit time resulted in an extreme condition, and, thus, we have
included the results of tests from the third batch in the overall analysis. Notably,
performance improves when these results are excluded; SCD-AMPS-2 improves to
a sensitivity of 90% (85–93%) and a specificity of 64% (55–72%), and SCD-
AMPS-3 improves to a sensitivity of 79% (73–83%) and a specificity of 70% (62–
78%).
Variability in the total blood drawn from each subject may have led to samples
receiving different concentrations of ethylenediaminetetraacetic acid (EDTA). We
found that both under treatment and over treatment with EDTA could lead to
false positives as a result of clotting or dehydration from high levels of EDTA (S5
Figure). The heparin coating on the capillary tubes had a negligible effect on
clotting. The eventual use of SCD-AMPS directly from finger prick samples
necessitates future work to incorporate effective anti-coagulants into the blood
collection aspect of the SCD-AMPS tests.
Based on our previous work [5], we set 48 hours after blood was drawn as a
cutoff for inclusion in the study. To test the effect of time after collection to
running tests, we also analyzed results from samples run after 48 hours. Binning
test results based on whether they were run in the first, second, or third 24 hour
time period after collection demonstrated a clear decline in specificity over time
(Fig. 4). Both SCD-AMPS-2 and SCD-AMPS-3 showed significant (p- value
57.5610
25 and 3.1610
24) decline between samples run within 24 hours and
those run after 48 hours. In both systems, sensitivity increased between the first
two time intervals (p-value 50.0031 and 1.5610
24) and decreased between the
last two time intervals (p-value 52.0610
24 and 0.0053) (Fig. 4). These results
indicate that storage of the blood samples has an impact on the effectiveness of the
tests. Storing erythrocytes in refrigeration can cause morphological changes that
may affect density [13]. Testing on samples collected directly from a finger prick
and run immediately could provide a more accurate prediction of performance of
SCD-AMPS.
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AMPS themselves contained EDTA. The combination of these anticoagulants with
blood that was already treated with anticoagulant may have led to increased
dehydration of erythrocytes and caused some false positives [14].
Future work on the development of SCD-AMPS as a rapid test should focus on
quality control to reduce batch to batch variations in density, evaluation of shelf-
Fig. 4. The sensitivity and specificity of SCD-AMPS as a function of the amount of time between
collecting samples and running tests. The specificity shows a decline over each 24 hour increment, with a
significant decline over 48 hours (p-value ,0.0005). The sensitivity increased between the first and second
time interval, but then decreased between the second and third interval (p-values ,0.01). The sample size
used for each time interval is provided below each bar.
doi:10.1371/journal.pone.0114540.g004
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concentration of anticoagulant in the devices, the creation of reliable positive and
negative controls, and assessing effectiveness when used on fresh blood samples
from finger pricks rather than venous blood that has been stored at 4˚C.
Performance on Subpopulations
We evaluated several subpopulations of interest to determine whether the SCD-
AMPS tests would be suitable for general screening (Table 4). One concern with a
diagnostic test based on the dense cells present in SCD is that other concurrent
conditions may lead to a decrease in the number of dense cells in circulation and
compromise the sensitivity of the diagnostic.
The high levels of Hb F in very young children (below 1 year old) has a
protective effect in SCD [15,16]. To test whether this effect would reduce
sensitivity, we evaluated a subpopulation of subjects with SCD that were between
6 months and 1 year of age, as well as a subpopulation of subjects with SCD that
had Hb F.20%. High levels of Hb F resulted in significantly decreased sensitivity
in both SCD-AMPS-2 and SCD-AMPS-3 (p-value ,0.001). Interestingly, SCD-
AMPS-2 showed a sensitivity for those between 6 months and 1 year of age (84%)
similar to that in the general population (87%). Sensitivity of SCD-AMPS-2 for
this subpopulation compared to sensitivity in children over 1 year old was not
significantly different (p-value 50.73).
The occurrence of a recent vaso-occlusive crisis has been reported to reduce the
percent of dense cells present in SCD [12]; we, therefore, tested a subpopulation
of patients with SCD who self-reported to have experienced a crisis in the last
48 hours (n533). In both SCD-AMPS-2 and SCD-AMPS-3, the sensitivity was
similar or higher for this subset compared to subjects who had not had a recent
crisis.
Severe anemia (defined as a hemoglobin concentration below 8 g/dL for
children over 5 years of age and 7 g/dL for children under 5 years old)[17]i s
common among patients with SCD. In both SCD-AMPS systems, however, those
with both SCD and severe anemia were detected with high sensitivity (.85%).
Microcytic, hypochromic anemia—the condition of having a mean corpuscular
volume below 80 fL, mean corpuscular hemoglobin below 26 pg/cell and
hemoglobin concentration below 13.5 g/dL for males and 21.0 g/dL for females—
could indicate the presence of iron deficiency anemia or a-thalassemia [18,19].
For both versions of SCD-AMPS, the sensitivity on patients with SCD that had
microcytic, hypochromic anemia was lower than on those without it (p-value
,0.05) (Table 4). The performance of density-based tests may be affected by
these conditions, which can decrease the density of erythrocytes. Despite reduced
performance, SCD-AMPS-2 still attained 80% (70–87%) sensitivity on those with
SCD and microcytic, hypochromic anemia.
12 subjects were found to have Hb S.50% but also to have Hb A.0%
(Table 3). This finding could indicate the subjects had b+ thalassemia and an Hb
S gene. Alternatively, these subjects may have been Hb SS patients who had
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designed to exclude recently transfused individuals, incomplete medical records
meant that study staff had to rely on the responses of participants and guardians
to surveys on whether a transfusion had been received in the past four months and
may have had some inaccuracies. In these 12 subjects, sensitivity of the test was
significantly decreased (p-value ,0.01) (Table 4).
Without the ability to perform genetic testing at the site of the study, we were
unable to confirm the concurrent presence of either a or b thalassemias.
Concurrent thalassemias could affect the number of dense cells in SCD [3,20].
The reduced performance of SCD-AMPS in samples with microcytic, hypochro-
mic anemia and in subjects with Hb S.50% but Hb A.0% indicates that the
effect of both a and b thalassemias could be important. Larger sample sizes and
confirmatory testing will be required to assess the full impact of these conditions
on diagnostic accuracy.
On both tests, specificity was not significantly different (p-value 51.0 for SCD-
AMPS-2, and p-value 50.39 for SCD-AMPS-3) for subjects with Hb AA and Hb
AS; sickle cell trait was not a major factor in creating false positives (S3 Table).
This characteristic sets density-based tests apart from solubility tests like Sickledex
[21].
Although the reduction in performance due to high Hb F merits some caution,
the high sensitivity for children between 6 months to 1 year of age, patients with a
recent vaso-occlusive crisis, and those with severe anemia suggests that the SCD-
AMPS-2 test should be useful as a screening or diagnostic tool for children as
young as 6 months old. Similarly, SCD-AMPS-3 should be beneficial if used on
children over 1 year of age.
Table 4. Sensitivity of SCD-AMPS tests on specific subpopulations.
SCD
Subjects SCD-AMPS-2 SCD-AMPS-3
Population Sensitivity CI p-val.
a Sensitivity CI p-val.
a
All 322 87% (82,90) — 75% (70,79) —
6–12 months 19 84% (62,94) 7.3610
21 53% (31,73) 3.1610
22
Recent Crisis
b 33 94% (80,98) 2.8610
21 88% (73,95) 8.9610
22
Hb F.20% 36 58% (42,70) 5.4610
26 39% (25,55) 1.5610
26
Micro. Hypo.
c 89 80% (70,87) 2.9610
22 62% (51,71) 1.6610
23
Sev. Anem.
d 112 93% (87,96) 1.6610
22 86% (78,91) 7.4610
24
Hb S.50%, Hb A.0%
e 12 50% (25,75) 2.0610
23 33% (14,61) 2.6610
23
ap-value from a two-sided version of Fisher’s exact test comparing samples from a subpopulation to the total population excluding the subpopulation.
bSelf-reported to have experienced body pain or vaso-occlusive crisis within previous 48 hours.
cMicro. Hypo. – Microcytic & hypochromic anemia defined as patients with a mean corpuscular volume below 80 fL, a mean corpuscular hemoglobin below
26 pg/cell and a hemoglobin concentration below 13.5 g/dL for males or below 21.0 g/dL for females.
dSev. Anem. – Severe anemia defined as a hemoglobin concentration below 8 g/dL for those over 5 years old, and 7 g/dL for those less than 5 years old.
eSubjects that may either have Hb Sb+ or may be Hb SS with a recent transfusion
doi:10.1371/journal.pone.0114540.t004
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One of the explicit goals of this trial was to establish whether the two different
tests (SCD-AMPS-2 and SCD-AMPS-3) had differences in performance in a large
clinical test. The threshold that produced the best combination of sensitivity and
specificity for each test was different. SCD-AMPS-2 performed best with the
criterion that the bottom of the tube had a full layer of red, whereas SCD-AMPS-3
was best when the more permissive minimum of any detectable amount of red
(including less than half a layer of red). Using these thresholds for each test, we
compared performance. SCD-AMPS-2 had a significantly (p-value ,0.01) higher
diagnostic accuracy (77% with C.I. 73–81%) than SCD-AMPS-3 (69% with C.I.
65–73%). An alternative to diagnostic accuracy is to use the diagnostic odds ratio
(DOR), defined as (true positives 6 true negatives)/(false positives 6 false
negatives). This ratio provides a measure of performance that is not as affected by
imbalances in recruitment of positives and negatives as diagnostic accuracy. The
logarithm of the DOR is normally distributed and allows us to calculate a standard
deviation (S.D.). With a log DOR of 2.3 (S.D. 50.2), SCD-AMPS-2 again
outperformed SCD-AMPS-3, which had a log DOR of 1.5 (S.D. 50.2).
One of the potential benefits of SCD-AMPS-3 over SCD-AMPS-2 is the
potential ability of the three-phase system to distinguish between the Hb SC and
Hb SS variant of SCD [5]. In this study, however, none of the patients had the Hb
SC genotype, and thus, we cannot conclude whether SCD-AMPS-3 can identify
Hb SC from this study. Hemoglobin C is more common in West Africa [22], and
a future study in that area could elucidate the ability of the test to distinguish this
subtype. In practical use, the choice of method could be selected based on known
epidemiological information about a specific region; SCD-AMPS-2, for example,
might be best in Zambia, while SCD-AMPS-3 may be more useful in Mali.
Individuals with Hb SS and Hb SC genotypes, furthermore, have different clinical
presentations that clinicians could take into consideration with the results of
testing.
Despite the inability to validate the ability of SCD-AMPS-3 to identify Hb SC
on positive samples, we could test whether SCD-AMPS-3 would incorrectly
identify an Hb SS sample as Hb SC. Of the 505 subjects tested, only three had an
SCD-AMPS-3 test with the majority of cells at the lower liquid interface (as
opposed to the upper liquid interface). One of these subjects also had a full layer
of red color at the bottom of the three-phase system and the HE results confirmed
the person as Hb SS. This result would correspond to a misidentification of Hb SS
as Hb SC in ,1% of cases. The other two tests with the majority of cells at the
lower liquid interface came from one person with Hb AS and one with Hb AA. In
both cases, no red color was detected at the bottom of SCD-AMPS-3, and,
therefore, both samples were correctly classified as not having SCD.
Even though the two SCD-AMPS tests demonstrated similar performance in
early validations studies at Harvard University [5], the trial in Zambia
demonstrates that SCD-AMPS-2 is more robust as a diagnostic test than SCD-
AMPS-3. Apart from the difference in the number of phases of these two systems,
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density of the bottom phases of the AMPSs. SCD-AMPS-2 was designed to have a
bottom phase with a density of 1.129 g/cm
3 while SCD-AMPS-3 had a less dense
bottom phase with a density of 1.120 g/cm
3. A reformulation of a three phase
system with a bottom phase with a higher density than the current SCD-AMPS-3
may provide a performance that is more similar to SCD-AMPS-2.
Capabilities of Rural Health Centers
A point-of-care diagnostic provides benefit when it is coupled to effective
interventions. Simple interventions (e.g., pneumococcal vaccine (PCV) and
prophylactic antibiotics) for sickle cell disease exist, and we sought to assess
whether rural health centers in Zambia had the capabilities to perform an SCD-
AMPS test and provide appropriate interventions.
Working with the U.S. Peace Corps in Zambia, we identified two Rural Health
Centers (RHCs)—Luena RHC and Ipusukilo RHC—in Northern Province to
carry out a demonstration of the rapid test and an assessment of capabilities to
care for patients with SCD. Our survey indicated that the clinical staff at both
RHCs was well acquainted with rapid tests for malaria, HIV, and syphilis and had
a supply of these tests. Neither clinic had a microscope or capabilities to diagnose
SCD with any of the currently available methods. Although both clinics lacked the
infrastructure to perform transfusions and did not have morphine, they did have
the ability to provide several other interventions that have been shown to reduce
mortality and ease the symptoms of sickle cell disease, including folic acid
supplements, intravenous fluids, antibiotics, antimalarials, and PCV (S4 Table)
[23–25].
Feedback on SCD-AMPS from End-users
The SCD-AMPS tests were designed to use minimal equipment in order to be
accessible to low-level clinics. Apart from the SCD-AMPS tests themselves, the
only other equipment necessary to perform a test is a microhematocrit centrifuge.
We used a centrifuge (CritSpin, Iris Sample Processing) powered by a car battery
with a DC-to-DC converter. The tests, supplies to perform a finger-prick safely,
the centrifuge, and the battery all fit into a backpack (Fig. 5) and were transported
from Lusaka to the RHCs by bus, shared taxis, and hitch-hiking.
We assessed the ability of the clinical staff to perform SCD-AMPS test by
presenting an educational session and a demonstration of the rapid test with a
focus on four steps: i) checking rapid tests for defects, ii) loading blood, iii)
centrifugation of tests, and iv) interpretation of rapid test results. The staff was
able to handle the rapid test and ask questions about the protocol and
interpretation. Afterwards, participants were surveyed to assess their comfort with
each of the four steps. Their familiarity and comfort with common lateral flow
rapid tests was also assessed as a benchmark for usability. Participants rated tests
using a five-point scale with 1 being ‘‘very difficult to use’’, 3 being ‘‘okay to use’’,
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flow tests, such a rapid diagnostic test for malaria, as 3.4.
Each step was rated for ease on the same 5 point scale. The initial set up was
given an average rating of 3.3. The loading step was given an average rating of 3.4.
Running the tests was given an average rating of 3.3. Reading results was given an
average rating of 3.3. Every step was, thus, comparable to the ease of use of
existing rapid tests.
Conclusions
A density-based diagnostic for sickle cell disease using AMPSs has the potential to
fill a critical healthcare gap in low-resource settings. Although sensitivity and
specificity are not as high as those of gold-standard methods like high
performance liquid chromatography and iso-electric focusing, these tests could
provide actionable information when coupled with patient history and clinical
presentation. Many clinics, such as those visited in Zambia, do not have the
infrastructure to support the equipment needed for gold-standard methods but
could run SCD-AMPS tests. Solubility tests, such as Sickledex (Streck), are often
used to screen for SCD in clinics in India and sub-Saharan Africa, but they cannot
differentiate between SCD and the largely benign, sickle cell trait. Although SCD-
AMPS do not distinguish Hb AA from sickle cell trait, SCD-AMPS do
discriminate between SCD and sickle cell trait.
The diagnostic ability of the SCD-AMPS depends on the presence of dense,
sickled cells in the blood. These cells may not be present in newborns, and hence
SCD-AMPS may not be appropriate for neonatal screening. Testing of SCD-
AMPS on children under six months old is required to ascertain the minimum age
at which the test will be useful for screening. After six months, however, the
Fig. 5. Equipment for the SCD-AMPS rapid test. All the equipment necessary to run the rapid test in a rural
clinic fits inside a backpack and were evaluated at rural health centers in Zambia.
doi:10.1371/journal.pone.0114540.g005
Field Evaluation of a Density-Based Rapid Test for Sickle Cell Disease
PLOS ONE | DOI:10.1371/journal.pone.0114540 December 9, 2014 18 / 24fraction of dense cells present is sufficient to allow use of SCD-AMPS-2. Coupled
with vaccination programs, screening children for SCD with an SCD-AMPS test
could provide useful information on prevalence.
SCD-AMPS are also acceptably simple to use; Initial demonstrations with staff
at rural clinics in Zambia indicate that SCD-AMPS tests are comparable to
standard rapid diagnostic tests for malaria in ease-of-use. Although the need for
centrifugation and a battery may make the test impractical for a community
health worker visiting households, we demonstrated that the equipment could be
used in rural health centers with access to solar power. The capability to diagnose
sickle cell disease at primary health centers and rural health centers in places like
Zambia would allow for the targeted use of appropriate interventions (e.g.,
vaccines, prophylactic penicillin, and supplements for folate and iron) [24,26,27].
These interventions could reduce child mortality and improve the quality of life
for those that live with undiagnosed sickle cell disease.
Materials and Methods
Chemicals
We used the following polymers: poly(ethylene glycol) (Sigma-Aldrich; MW
520000 Da), Ficoll (Sigma-Aldrich; MW 570000 Da and 400000 Da), dextran
(Spectrum Chemical; 500000 Da), and poly(vinyl alcohol) (PVA) (Polysciences;
MW 53000 Da)—formed by hydrolyzing 75% of poly(vinyl acetate). Solutions of
AMPSs contained the following chemicals: ethylenediaminetetraacetic acid
disodium salt (EDTA) (Sigma-Aldrich), potassium phosphate monobasic (EMD),
sodium phosphate dibasic (Mallinkrodt AR), sodium chloride (EMD), MgCl2
(USB), and Nycodenz (Axis-Shield PoC).
Components
We purchased the following components to assemble our rapid tests: heparinized,
polycarbonate microhematocrit tubes (Iris Sample Processing), vinyl putty
(Critoseal, Leica), silicone rubber tubing with an inner diameter of 1.02 mm and
an outer diameter of 2.06 mm (Helix Mark, Helix Medical), glue (Krazy Glue),
rubber caps (Critocaps, Leica), foil-lined pouches (Vapor-Flex VF48, LPS
Industries), and shipping labels (5163, Avery). Templates to punch holes in
capillary tubes and meter the volume of polymer to fill were printed in
acrylonitrile butadiene styrene (ABS) using a 3D printer (Fortus 400mc,
Dimension).
Blood collection used vacutainers (Becton Dickinson) coated with EDTA for
2 mL. Aliquots of the collected blood were transferred to vacutainers with no
coating (Becton Dickinson).
Field Evaluation of a Density-Based Rapid Test for Sickle Cell Disease
PLOS ONE | DOI:10.1371/journal.pone.0114540 December 9, 2014 19 / 24Standard Blood Tests
CBCs were performed at UTH using a Sysmex XT 2000i hematology analyzer.
Calibrations and quality controls were performed daily. HE was performed at
UTH using a semi-automated SAS1/2 from Helena Biosciences, LLC. Gels and
hemoglobin controls were purchased from Helena Biosciences, LLC through their
Sonergy Diagnostics, the local vendor in Zambia. Controls were run with every gel
to ensure proper calibration and performance of the gels. For quantitative analysis
of hemoglobin, we scanned gels using a transmission scanner (Epson Perfection
V550) and analyzed the image using Platinum 4.1 software (Helena Biosciences).
Classification of Subjects Based on Results from Hemoglobin
Electrophoresis
Most subjects were easily classified based on the results from hemoglobin
electrophoresis. No Hb C was detected in any of the subjects. Subjects with no
detectable Hb S were classified as HbAA. Subjects with Hb A.50% and Hb S
,50% were classified as Hb AS. Patients with no detectable Hb A and with
detectable Hb S were classified as Hb SS. Hb F, when present, was quantified for
all subjects. Of the over 500 subjects tested, we were then left with 12 subjects that
had Hb S.50% but also had detectable Hb A. We classified these subjects as
positive for SCD for the purposes of the study. All had either elevated reticulocyte
counts or low hemoglobin concentrations. Their Hb S concentrations ranged
from 54–78%. Based on the CBC results from these subjects, three of the subjects
had a microcytic and hypochromic anemia. These 12 subjects may be SCD
patients with Hb Sb+ or they may have been transfused. In this study, these
subjects were classified as having SCD.
Statistics
Statistical analysis was done using R (http://www.r-project.org). We used Bayesian
confidence intervals (Jeffreys prior) for the binary data that was used to make
point estimates of sensitivity and specificity. We used a two-sided version of
Fisher’s exact test to test for significant differences between performances of the
SCD-AMPS on different categorical data (e.g., recent crisis, different batches of
SCD-AMPS, samples stored at different time intervals).
Human Subjects Research
We obtained written consent from all participants and/or their legal guardians for
the study of SCD-AMPS at UTH and from participants from the Harvard team
who provided samples for demonstrations. The consenting process, protocol, and
all associated materials were approved by the Institutional Review Board (IRB) of
the Faculty of Arts and Sciences at Harvard University, the Committee on the Use
of Human Subjects (CUHS) (Federal Wide Assurance (FWA) # 00004837, IRB
Identification # 00000109) under the reference numbers 23799 and 16779. The
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Board in Lusaka, Zambia, the ERES Converge Committee (FWA # 00011697, IRB
Identification # 00005948), under the reference number 2013-Jan-013. Verbal
consent was obtained for participants of the survey of health workers in rural
health centers in Zambia. The survey instrument did not include any identifying
information, nor collected any information deemed potentially private by either
CUHS or ERES Converge. An approved script was used to explain the survey and
included a checkbox to indicate whether consent was provided. This survey of
rural health workers in Zambia and the oral consent process was deemed exempt
of need for full IRB review by CUHS (Ref. No. IRB13-1519) and underwent full
IRB review and approval by ERES Converge (Ref. No. 2013-Sept-007).
Supporting Information
Additional details regarding the fabrication, testing, and evaluation of the SCD-
AMPS tests and the samples are provided in S1 Text.
Supporting Information
S1 Figure. Schematic of the fabrication of SCD-AMPS tests. Plastic
microhematocrit tubes (A) insert into a holder (B) and can then be punctured
with a pushpin (C) and metered with a marker (D). After blowing out debris with
an airgun, we add a silicone sleeve to cover the hole in the side of the tube (E). We
then added a well-mixed AMPS solution (F) and seal the bottom of the tube with
putty (G). After a quick spin (H), the initial metering mark is removed (I) and
replaced with a line to mark the level of the volume of the test (J). We then seal
the bottom of the test with glue (K) and cover the open end with a rubber cap (L).
A dozen completed tests fit into a foil lined pouch (M). We add 4 mL of water
(N) and seal the package (O).
doi:10.1371/journal.pone.0114540.s001 (TIF)
S2 Figure. Process to perform a rapid test for SCD with SCD-AMPS. The user
opens a packet and pour out the water (A) to retrieve the rapid tests (B). She then
removes the rubber cap and centrifuges the test for 2 minutes (C). After checking
that the phases have formed and the proper volume of liquid is present (D), the
user slides down the silicone sleeve to reveal the punched hole (E) and wicks
blood into the test until it reaches the hole (F). The user then slides the sleeve back
over the hole (G) and centrifuges the test for 10 minutes (H). The test can then be
read by eye (I).
doi:10.1371/journal.pone.0114540.s002 (TIF)
S3 Figure. Flow diagram of recruitment and testing for the study to evaluate
SCD-AMPS-2 and SCD-AMPS-3. The reference test was hemoglobin (Hb)
electrophoresis. SCD-AMPS-2 tests were classified as positive if a full layer of red
or more was present at the bottom of the tube. SCD-AMPS-3 was classified as
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PLOS ONE | DOI:10.1371/journal.pone.0114540 December 9, 2014 21 / 24positive if there was a detectable red color at the bottom of the tube, including less
than half a layer of red.
doi:10.1371/journal.pone.0114540.s003 (TIF)
S4 Figure. The performance of the rapid test varied between batches shipped to
Zambia. The diagnostic accuracy was calculated for each of the five batches of
rapid tests evaluated in Zambia show significant variation for both SCD-AMPS-2
(white) and SCD-AMPS-3 (light gray). Both the combined results (All) and
individual batch results (1–5) are shown. Batch 1 showed the good discriminative
ability with a diagnostic accuracy over 0.8 (80%) for both tests. Error bars indicate
95% confidence intervals. The number of subjects in each batch are listed in
parentheses below the batch number.
doi:10.1371/journal.pone.0114540.s004 (TIF)
S5 Figure. Effect of anticoagulants on the performance of SCD-AMPS. Digital
analysis of the red intensity at the bottom of the SCD-AMPS tests for a normal
subject whose blood was treated with different concentrations of anticoagulant
(EDTA). Samples were run in standard SCD-AMPS tubes treated with heparin
(treated capillary) as well as SCD-AMPS loaded in tubes without any coating
(untreated capillary). In all cases, the samples collected in the standard
concentration of EDTA (5 mM) showed the least amount of red at the bottom of
the tube. Variability in the concentration of anticoagulant during blood collection
could be a source of false positives. Error bars represent standard error of the
mean of triplicate experiments.
doi:10.1371/journal.pone.0114540.s005 (TIF)
S1 Table. Time cutoffs for testing samples in the study.
doi:10.1371/journal.pone.0114540.s006 (DOCX)
S2 Table. Characterization of each batch of SCD-AMPS used in the study.
doi:10.1371/journal.pone.0114540.s007 (DOCX)
S3 Table. Specificity of SCD-AMPS on HbAA and HbAS (negative samples).
doi:10.1371/journal.pone.0114540.s008 (DOCX)
S4 Table. Assets at Rural Health Centers to treat SCD.
doi:10.1371/journal.pone.0114540.s009 (DOCX)
S1 Text. Supporting Information for Evaluation of a Density-based Rapid
Diagnostic Test for Sickle Cell Disease in a Clinical Setting in Zambia.
doi:10.1371/journal.pone.0114540.s010 (DOCX)
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